[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507446":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":40,"centralContacts":44,"locations":49,"responsibleParty":217,"collaborators":33,"id":219,"slug":220,"hasResults":221,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":33,"eligibilityCriteria":225,"healthyVolunteers":221,"sex":226,"minAge":227,"maxAge":33,"enrollmentInfo":228,"targetDuration":33,"studyType":231,"phases":232,"briefSummary":235,"conditions":236,"keywords":241,"overallStatus":52,"whyStopped":33,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},{"fullName":5,"class":6},"Tango Therapeutics, Inc.","INDUSTRY",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD",[13,14],"Drug: TNG260","Drug: Pembrolizumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion in NSCLC with KRAS Mutation","Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Dose Expansion in NSCLC with KRAS Wild type","Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Dose Expansion in Advanced or Metastatic Solid Tumors","Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab",[13,14],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","TNG260","CoREST inhibitor, administered orally",[9,24,16,20],null,{"type":29,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Pembrolizumab","Pembrolizumab, an anti-PD-1 antibody, administered intravenously",[9,24,16,20],[39],"Keytruda",[41],{"name":42,"affiliation":5,"role":43},"Adam Crystal, MD, PhD","STUDY_DIRECTOR",[45],{"name":42,"role":46,"phone":47,"phoneExt":33,"email":48},"CONTACT","8573204899","clinicaltrials@tangotx.com",[50,68,81,94,107,120,132,145,155,168,181,193,206],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"UCLA Hematology\u002FOncology","RECRUITING","Santa Monica","California","90404","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-118.49138,34.01949,{"lat":62,"lon":61},[65],{"name":66,"role":67,"phone":33,"phoneExt":33,"email":33},"Jonathan Goldman, MD","PRINCIPAL_INVESTIGATOR",{"facility":69,"status":52,"city":70,"state":71,"zip":72,"country":56,"countryCode":57,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"SCRI at HealthOne","Denver","Colorado","80218",{"type":59,"coordinates":74},[75,76],-104.9847,39.73915,{"lat":76,"lon":75},[79],{"name":80,"role":67,"phone":33,"phoneExt":33,"email":33},"Gerald Falchook, MD",{"facility":82,"status":52,"city":83,"state":84,"zip":85,"country":56,"countryCode":57,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Florida Cancer Specialists","Sarasota","Florida","34232",{"type":59,"coordinates":87},[88,89],-82.53065,27.33643,{"lat":89,"lon":88},[92],{"name":93,"role":67,"phone":33,"phoneExt":33,"email":33},"Judy Wang, MD",{"facility":95,"status":52,"city":96,"state":97,"zip":98,"country":56,"countryCode":57,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":59,"coordinates":100},[101,102],-71.05977,42.35843,{"lat":102,"lon":101},[105],{"name":106,"role":67,"phone":33,"phoneExt":33,"email":33},"Mark Awad, MD, PhD",{"facility":108,"status":52,"city":109,"state":110,"zip":111,"country":56,"countryCode":57,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Henry Ford Health System","Detroit","Michigan","48202",{"type":59,"coordinates":113},[114,115],-83.04575,42.33143,{"lat":115,"lon":114},[118],{"name":119,"role":67,"phone":33,"phoneExt":33,"email":33},"Shiresh Gadgeel, MD",{"facility":121,"status":52,"city":122,"state":110,"zip":123,"country":56,"countryCode":57,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"START MidWest","Grand Rapids","49546",{"type":59,"coordinates":125},[126,127],-85.66809,42.96336,{"lat":127,"lon":126},[130],{"name":131,"role":67,"phone":33,"phoneExt":33,"email":33},"Manish Sharma, MD",{"facility":133,"status":52,"city":134,"state":135,"zip":136,"country":56,"countryCode":57,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"NYU Langone Hematology Oncology Associates-Mineola","Mineola","New York","11501",{"type":59,"coordinates":138},[139,140],-73.64068,40.74927,{"lat":140,"lon":139},[143],{"name":144,"role":67,"phone":33,"phoneExt":33,"email":33},"Salman Punekar, MD",{"facility":146,"status":52,"city":135,"state":135,"zip":147,"country":56,"countryCode":57,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"New York University Langone Health","10016",{"type":59,"coordinates":149},[150,151],-74.00597,40.71427,{"lat":151,"lon":150},[154],{"name":144,"role":67,"phone":33,"phoneExt":33,"email":33},{"facility":156,"status":52,"city":157,"state":158,"zip":159,"country":56,"countryCode":57,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Sarah Cannon Tennessee Oncology","Nashville","Tennessee","37203",{"type":59,"coordinates":161},[162,163],-86.78444,36.16589,{"lat":163,"lon":162},[166],{"name":167,"role":67,"phone":33,"phoneExt":33,"email":33},"David Spigel, MD",{"facility":169,"status":52,"city":170,"state":171,"zip":172,"country":56,"countryCode":57,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"US Oncology Investigational Products Center","Dallas","Texas","75246",{"type":59,"coordinates":174},[175,176],-96.80667,32.78306,{"lat":176,"lon":175},[179],{"name":180,"role":67,"phone":33,"phoneExt":33,"email":33},"Kartik Konduri, MD",{"facility":182,"status":52,"city":183,"state":171,"zip":184,"country":56,"countryCode":57,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"The University of Texas MD Anderson Cancer Center","Houston","77030",{"type":59,"coordinates":186},[187,188],-95.36327,29.76328,{"lat":188,"lon":187},[191],{"name":192,"role":67,"phone":33,"phoneExt":33,"email":33},"Ferdinandos Skoulidis, MD",{"facility":194,"status":52,"city":195,"state":196,"zip":197,"country":56,"countryCode":57,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"NEXT Oncology Virginia","Fairfax","Virginia","22031",{"type":59,"coordinates":199},[200,201],-77.30637,38.84622,{"lat":201,"lon":200},[204],{"name":205,"role":67,"phone":33,"phoneExt":33,"email":33},"Alex Spira, MD",{"facility":169,"status":52,"city":207,"state":196,"zip":208,"country":56,"countryCode":57,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"Norfolk","23502",{"type":59,"coordinates":210},[211,212],-76.28522,36.84681,{"lat":212,"lon":211},[215],{"name":216,"role":67,"phone":33,"phoneExt":33,"email":33},"Jedrzej Wykretowicz, MD",{"type":218,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100507446","phase-1-study-of-tng260-and-an-anti-pd-antibody-in-stk11-mutated-solid-tumors-100507446",false,"NCT05887492","Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","A Phase 1\u002F2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors","Inclusion Criteria:\n\n* Is ≥18 years of age at the time of signature of the main study ICF.\n* Has ECOG performance status of 0 or 1.\n* Has measurable disease based on RECIST v1.1.\n* All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method\n* Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor.\n* Adequate organ function\u002Freserve per local labs\n* Adequate liver function per local labs\n* Adequate renal function per local labs\n* Negative serum pregnancy test result at screening\n* Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n* Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients\n* Uncontrolled intercurrent illness that will limit compliance with the study requirements\n* Active infection requiring systemic therapy\n* Currently participating in or has planned participation in a study of another investigational agent or device\n* Impairment of GI function or disease that may significantly alter the absorption of oral TNG260\n* Active prior or concurrent malignancy.\n* Central nervous system metastases associated with progressive neurological symptoms\n* Current active liver disease from any cause\n* Clinically relevant cardiovascular disease\n* A female patient who is pregnant or lactating","ALL","18 Years",{"count":229,"type":230},126,"ESTIMATED","INTERVENTIONAL",[233,234],"PHASE1","PHASE2","The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.\n\nThe main question\\[s\\] it aims to answer are:\n\n* the recommended dose for Phase 2\n* to evaluate the safety and tolerability of the combination therapy\n* to determine the pharmacokinetics of TNG260\n* to evaluate the initial antineoplastic activity\n\nParticipants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.",[237,238,239,240],"Non Small Cell Lung Cancer","Solid Tumors, Adult","Lung Cancer","Lung Adenocarcinoma",[242,243,244],"STK11","KRAS wild type","LKB1","2025-11-14",{"date":247,"type":248},"2025-11-18","ACTUAL",{"date":250,"type":248},"2023-06-12",{"date":252,"type":230},"2026-06",{"name":5,"class":6},13]